Select Language:
A recent international study has revealed that combining two cancer drugs could significantly slow the progression of a particularly dangerous form of prostate cancer in certain men. Led by researchers at University College London (UCL), the study involved hundreds of patients from multiple countries.
Published in the journal Nature Medicine, these findings offer renewed hope for patients with prostate cancer that harbors specific genetic mutations, making the disease more difficult to treat.
Prostate cancer ranks among the most common cancers affecting men. The prostate, a small gland located below the bladder, plays a role in semen production. As men age, prostate cells can grow uncontrollably, forming tumors. Often, prostate cancer develops slowly and can be managed effectively with treatment.
However, some cases become aggressive, spreading to areas like bones and lymph nodes. Once the cancer metastasizes, treatment becomes more challenging and the risk to life increases.
Researchers have long sought to understand why some prostate tumors become more aggressive than others. A key clue involves a group of genes responsible for repairing damaged DNA, known as homologous recombination repair (HRR). These genes act as a cellular repair crew, fixing DNA errors that could otherwise trigger cancer. When these genes function properly, they help prevent cancer from developing. But when mutated or damaged, DNA repair is impaired, leading to faster cancer growth and spread.
Approximately 25% of men with advanced prostate cancer carry mutations in HRR-related genes, including well-known ones like BRCA1 and BRCA2—genes also linked to breast and ovarian cancers. Other important genes, such as CHEK2 and PALB2, can also contribute. When these genes aren’t working correctly, the cancer tends to become more aggressive and less responsive to standard treatments.
To explore new treatment options, scientists conducted the large-scale AMPLITUDE trial, a Phase III clinical study. This phase typically tests a promising treatment in a broad patient population to verify its safety and effectiveness.
The trial included 696 men from 32 countries, all with metastatic prostate cancer who had not yet started specific treatment for this stage. The average age of participants was 68, and every participant had a mutation in an HRR gene.
Participants were divided into two groups. One received the standard treatment, which includes abiraterone acetate and prednisone—medications that slow cancer growth by lowering male hormone levels that fuel tumor development. The other group received the same standard treatment plus niraparib, a targeted drug known as a PARP inhibitor.
PARP inhibitors are designed to exploit weaknesses in cancer cells with DNA repair deficiencies. By blocking another repair pathway, these drugs cause cancer cells to accumulate lethal levels of DNA damage, leading to cell death. Healthy cells are less affected because their repair mechanisms remain functional.
The study was double-blind, meaning neither the patients nor the doctors knew who received niraparib or a placebo, reducing bias and increasing the reliability of results.
After a median follow-up of about 30.8 months, the data showed a clear benefit for those on the combination therapy. Patients taking niraparib with standard treatment had a 37% lower chance of their cancer worsening compared to those on standard therapy alone.
The most remarkable results appeared in patients with mutations in BRCA1 or BRCA2. In this subgroup, the risk of disease progression dropped by nearly half—about 48%. This suggests that the drug combination could be especially potent for patients with these specific genetic weaknesses.
Additionally, symptom worsening took longer in the niraparib group. Only 16% experienced significant symptom progression, compared to 34% in the placebo group. This indicates that many patients maintained their quality of life longer with the combination treatment.
There were signs that the new therapy might boost overall survival, but longer follow-up is necessary to confirm this potential benefit.
As with many cancer treatments, side effects were more common among patients taking niraparib. Some experienced anemia, a condition where red blood cell levels are too low, and high blood pressure was also reported more frequently. About a quarter of patients needed blood transfusions during treatment, and there were slightly more treatment-related deaths in the niraparib group, though numbers remained small. Most patients were still able to continue treatment despite these issues.
The study underscores the importance of genetic testing in cancer care. By identifying HRR gene mutations early, clinicians can better determine which patients are most likely to benefit from targeted therapies like niraparib.
Annually, around 1.5 million men are diagnosed with prostate cancer worldwide. In the United States alone, over 56,000 men are diagnosed each year, with roughly 12,000 deaths. Because of its prevalence, even modest advances in treatment can significantly impact public health.
The AMPLITUDE trial was sponsored by Janssen Research and Development, part of Johnson & Johnson. These results suggest that combining genetic-driven therapies with hormone treatments could be a key step toward personalized cancer care.
Overall, the research demonstrates that adding niraparib to standard therapy can delay disease progression in men with certain genetic forms of advanced prostate cancer. Still, potential risks and side effects should be carefully considered. More long-term studies are vital to determine if this approach improves overall survival and to identify which patients are the most suitable candidates.
Despite the need for further research, these findings mark an important milestone in tailoring cancer treatments based on individual genetic profiles.
ChatGPT
Perplexity
Gemini AI
Grok AI
